MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2020-219724

Медицинская библиотека · Annals of the rheumatic diseases · 2021

EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.

Alunno Alessia, Najm Aurélie, Machado Pedro M, Bertheussen Heidi, Burmester Gerd R, Carubbi Francesco, De Marco Gabriele, Giacomelli Roberto, Hermine Olivier, Isaacs John D, Koné-Paut Isabelle, Magro-Checa César, McInnes Iain, Meroni Pier Luigi, Quartuccio Luca, Ramanan Athimalaipet V, Ramos-Casals Manuel, Rodríguez Carrio Javier, Schulze-Koops Hendrik, Stamm Tanja A, Tas Sander W, Terrier Benjamin, McGonagle Dennis G, Mariette Xavier

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Severe systemic inflammation associated with some stages of COVID-19 and in fatal cases led therapeutic agents developed or used frequently in Rheumatology being at the vanguard of experimental therapeutics strategies. The aim of this project was to elaborate EULAR Points to consider (PtCs) on COVID-19 pathophysiology and immunomodulatory therapies.

METHODS

PtCs were developed in accordance with EULAR standard operating procedures for endorsed recommendations, led by an international multidisciplinary Task Force, including rheumatologists, translational immunologists, haematologists, paediatricians, patients and health professionals, based on a systemic literature review up to 15 December 2020. Overarching principles (OPs) and PtCs were formulated and consolidated by formal voting.

RESULTS

Two OPs and fourteen PtCs were developed. OPs highlight the heterogeneous clinical spectrum of SARS-CoV-2 infection and the need of a multifaceted approach to target the different pathophysiological mechanisms. PtCs 1-6 encompass the pathophysiology of SARS-CoV-2 including immune response, endothelial dysfunction and biomarkers. PtCs 7-14 focus on the management of SARS-CoV-2 infection with immunomodulators. There was evidence supporting the use of glucocorticoids, especially dexamethasone, in COVID-19 cases requiring oxygen therapy. No other immunomodulator demonstrated efficacy on mortality to date, with however inconsistent results for tocilizumab. Immunomodulatory therapy was not associated with higher infection rates.

CONCLUSIONS

Multifactorial pathophysiological mechanisms, including immune abnormalities, play a key role in COVID-19. The efficacy of glucocorticoids in cases requiring oxygen therapy suggests that immunomodulatory treatment might be effective in COVID-19 subsets. Involvement of rheumatologists, as systemic inflammatory diseases experts, should continue in ongoing clinical trials delineating optimal immunomodulatory therapy utilisation in COVID-19.

Для цитирования: Alunno Alessia, Najm Aurélie, Machado Pedro M, Bertheussen Heidi, Burmester Gerd R, Carubbi Francesco, De Marco Gabriele, Giacomelli Roberto, Hermine Olivier, Isaacs John D, Koné-Paut Isabelle, Magro-Checa César, McInnes Iain, Meroni Pier Luigi, Quartuccio Luca, Ramanan Athimalaipet V, Ramos-Casals Manuel, Rodríguez Carrio Javier, Schulze-Koops Hendrik, Stamm Tanja A, Tas Sander W, Terrier Benjamin, McGonagle Dennis G, Mariette Xavier. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.. Annals of the rheumatic diseases. 2021. DOI: 10.1136/annrheumdis-2020-219724.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.